[Skip to Navigation]
December 13, 2021

New Treatments for Migraine—Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe

Author Affiliations
  • 1Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2022;182(2):101-102. doi:10.1001/jamainternmed.2021.7168

Migraine is one of the most prevalent and disabling disorders worldwide.1 In addition to triptans, which are used as abortive medications for acute migraine attacks, the US Food and Drug Administration (FDA) has approved several preventive treatments for migraine, including propranolol, topiramate, and onabotulinumtoxinA. Although most of these therapies are relatively inexpensive or available as generics, patients frequently develop symptoms refractory to these agents.2

Add or change institution